ArticleAmerican journal of translational research2025
Long-term effects of metformin versus sodium glucose transporter 2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gene-Guided Therapy in Type 2 Diabetes Mellitus: An Integrative Review of the Pharmacogenetics of Metformin and Sodium-Glucose Cotransporter-2 Inhibitors.Endocrinology, diabetes & metabolism · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo compare the long-term cardiovascular effects of Metformin and sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM).
methodsA retrospective study was conducted on 692 T2DM patients treated between January 2020 and January 2023. Patients were divided into two groups: SGLT2i group (n = 460) and Metformin group (n = 232) according to their treatment protocol. Data on demographics, blood glucose/lipid profiles, echocardiographic parameters, and cardiovascular outcomes were collected over a 2-year follow-up period. Outcomes included myocardial infarction (MI), stroke, mortality, and hospitalization for heart failure (HHF).
resultsBoth treatments significantly reduced blood glucose levels, with Metformin showing greater improvements in glycated hemoglobin (HbA1c). SGLT2i demonstrated superior reductions in triglycerides and total cholesterol levels. Echocardiography revealed enhanced diastolic function with SGLT2i. Moreover, SGLT2i significantly reduced MI and HHF risk, though safety profiles were similar except for higher genital infection incidence in the SGLT2i group.
conclusionsWhile Metformin remains effective for glycemic control, SGLT2i offers distinct cardiovascular benefits, notably in reducing the risks of MI and HHF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.